Table 4 Comparative in vivo pharmacokinetic studies data between treatment groups
Parameter | Standard group | Test group I | Test group II | Test group III |
|---|---|---|---|---|
ZOCOR tablet (10 mg/kg)–oral administration (marketed simvastatin formulation) | Simvastatin Nlc Suspension (10 mg/kg)–oral administration | Simvastatin loaded transdermal patch (10 mg/kg)–transdermal route | NLC loaded transdermal patch (10 mg/kg)–transdermal route | |
Tmax (h) | 2 | 8 | 9.5 | 12 |
Cmax (μg/ml) | 0.1410 | 0.1148 | 0.086 | 0.065 |
AUC0-α (μg/ml h) | 8.8695 | 84.8520 | 132.5082 | 163.0397 |
MRT0-α (h) | 11 | 23 | 38 | 44 |
\( \mathrm{F}\ \mathrm{rel}=\frac{{\left(\mathrm{AUC}\right)}_{\mathrm{test}}\cdotp {\left(\mathrm{Dose}\right)}_{\mathrm{std}}}{{\left(\mathrm{AUC}\right)}_{\mathrm{test}}\cdotp {\left(\mathrm{Dose}\right)}_{\mathrm{test}}} \) | Bioavailability enhanced by 9.64% | Bioavailability enhanced by 14.95% | Bioavailability enhanced by 18.40% | |